UroGen Pharma Ltd.Urbane shares traded decrease Wednesday after the Oncologic Medicine Advisory Committee (ODAC) of the Meals and Drug Administration voted towards the profit/danger of UGN-102 (mitomycin) for intravesical resolution.
What To Know: The committee voted 4 sure to 5 no that the profit/danger of UGN-102 for intravesical resolution was favorable for the remedy of recurrent Low-Grade Intermediate-Danger Non-Muscle Invasive Bladder Most cancers.
The vote comes after the committee reviewed scientific information supporting the efficacy and security of UGN-102, together with the outcomes from the Section 3 ENVISION research.
Liz Barrettpresident and CEO of UroGen, mentioned, “Whereas we’re disillusioned by at present’s consequence, we proceed to consider our scientific information assist UGN-102 for the remedy of recurrent LG-IR-NMIBC, a illness with no FDA-approved therapies. The FDA rigorously considers the unbiased recommendation from ODAC, and we look ahead to working with the FDA as they full their evaluation of the applying for UGN-102.”
URGN Value Motion: UtroGen inventory closed 44.69% decrease at $4.17, in response to information from Benzinga Professional.
See Additionally:
• CoreWeave Inventory Hits All-Time Excessive: What’s Going On?
Picture: Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
